Analyst Activity – Sanford C. Bernstein Initiates Coverage On Alnylam Pharmaceuticals (NASDAQ:ALNY) With a Outperform

ME Staff
-
0

Analyst Ratings For Alnylam Pharmaceuticals (NASDAQ:ALNY)

Today, Sanford C. Bernstein initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform with a price target of $99.00.

There are 1 sell rating, 6 hold ratings, 11 buy ratings on the stock.

The current consensus rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) is Buy (Score: 2.56) with a consensus target price of $81.17 per share, a potential 0.49% downside.

Some recent analyst ratings include

  • 7/27/2017-Sanford C. Bernstein initiated coverage with a Outperform rating.
  • 7/11/2017-Cowen and Company Reiterated Rating of Buy.
  • 7/10/2017-Morgan Stanley Reiterated Rating of Equal Weight.
  • 7/10/2017-Needham & Company LLC Reiterated Rating of Buy.
  • 7/10/2017-Chardan Capital Reiterated Rating of Buy.

Recent Insider Trading Activity For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 89.00%.

  • On 5/31/2017 Sanofi, Major Shareholder, bought 297,501 with an average share price of $71.87 per share and the total transaction amounting to $21,381,396.87. View SEC Filing
  • On 5/30/2017 Laurie Keating, SVP, bought 11,500 with an average share price of $65.35 per share and the total transaction amounting to $751,525.00. View SEC Filing
  • On 5/23/2017 Akshay Vaishnaw, EVP, sold 11,000 with an average share price of $75.00 per share and the total transaction amounting to $825,000.00. View SEC Filing
  • On 5/16/2017 Michael Mason, VP, sold 9,375 with an average share price of $70.00 per share and the total transaction amounting to $656,250.00. View SEC Filing
  • On 5/15/2017 Akshay Vaishnaw, SVP, sold 43,750 with an average share price of $65.00 per share and the total transaction amounting to $2,843,750.00. View SEC Filing
  • On 1/25/2017 Philip A Sharp, Director, sold 15,000 with an average share price of $37.95 per share and the total transaction amounting to $569,250.00. View SEC Filing
  • On 1/18/2017 Philip A Sharp, Director, sold 15,000 with an average share price of $37.83 per share and the total transaction amounting to $567,450.00. View SEC Filing

Recent Trading Activity for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals closed the previous trading session at 81.30 down -0.27 -0.33% with 479,318 shares trading hands.